Table 1.
Characteristics of type 2 diabetes patients
|
1998 N = 946 |
1999 N = 1075 |
2000 N = 1248 |
2001 N = 1374 |
2002 N = 1295 |
2003 N = 1485 |
|
| Patient characteristics | ||||||
| Age (years) | 68 ± 11 | 68 ± 11 | 67 ± 11 | 67 ± 11 | 67 ± 11 | 67 ± 11 |
| Female sex (%) | 57% | 58% | 57% | 57% | 57% | 55% |
| Duration of diabetes (years) | 5 (2–10) | 5 (2–10) | 5 (2–10) | 4 (2–9) | 4 (2–9) | 5 (2–9) |
| History of MI/AP | 25% | 22% | 21% | 19% | 18% | 18% |
| Body mass index (kg/m2) | 29.0 ± 4.7 | 29.0 ± 4.7 | 29.4 ± 4.8 | 29.5 ± 4.8 | 29.5 ± 4.7 | 29.5 ± 4.8 |
| HbA1c (% units) | 7.5 ± 1.2 | 7.4 ± 1.2 | 7.3 ± 1.3 | 7.0 ± 1.2 | 7.0 ± 1.2 | 7.0 ± 1.2 |
| TC/HDL ratio | 5.3 ± 1.6 | 4.8 ± 1.3 | 4.5 ± 1.2 | 4.4 ± 1.2 | 4.1 ± 1.1 | 3.9 ± 1.1 |
| Systolic blood pressure (mmHg) | 155 ± 25 | 150 ± 23 | 150 ± 23 | 146 ± 20 | 145 ± 21 | 148 ± 21 |
| Diastolic blood pressure (mmHg) | 84 ± 11 | 82 ± 11 | 81 ± 11 | 80 ± 10 | 80 ± 10 | 84 ± 11 |
| Number of glucose-lowering drugs | ||||||
| None | 20% | 17% | 18% | 20% | 23% | 20% |
| 1 oral | 43% | 43% | 41% | 39% | 36% | 39% |
| ≥ 2 oral | 22% | 25% | 26% | 26% | 28% | 26% |
| Insulin (with or without oral drugs) | 15% | 15% | 15% | 15% | 13% | 14% |
| Use of cardiovascular drugs | ||||||
| Lipid-lowering drugs | 12% | 15% | 22% | 27% | 30% | 34% |
| Antihypertensive drugs | 48% | 51% | 57% | 63% | 66% | 69% |
| ACE-inhibitors or ARBs | 24% | 26% | 30% | 36% | 42% | 45% |
| Antiplatelet drugs | 22% | 22% | 23% | 25% | 25% | 26% |
Values are percentages, means ± standard deviations or median (interquartile range).
MI, myocardial infarction; AP, angina pectoris; HbA1c, haemoglobin A1c; TC, total cholesterol; HDL, high-density lipoprotein; ACE-inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers.